Two International Biopharmaceutical Organizations Sign Agreements with eResearchTechnology Totaling More Than $1.7 Million for T
21 February 2004 - 1:01AM
PR Newswire (US)
Two International Biopharmaceutical Organizations Sign Agreements
with eResearchTechnology Totaling More Than $1.7 Million for
Thorough Phase 1 ECG Studies eResearchTechnology to Provide Cardiac
Safety Monitoring and Information Distribution Services
PHILADELPHIA, Feb. 20 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received
agreements for more than $1.7 million in cardiac safety monitoring
and services from two international biopharmaceutical organizations
for two drug candidates in clinical development. The agreements
cover an extensive Phase I study for each compound. eRT is
providing comprehensivesupport including the provision, training
and ongoing assistance required for effective use of digital
12-lead Holter equipment designed to facilitate 24-hour digital
recording of cardiac safety data that is subsequently provided to
eRT for analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
Each study is targeted for completion over a 90-day period. "We are
pleased to have been awarded these important studies, which
illustrate the continued adoption of emerging FDA guidelines and
international standards that designate the Thorough Phase I ECG
Study as the definitive approach to determining the cardiac effects
of new therapies on healthy volunteers," said Scott Grisanti,
senior vice president of business development and chief marketing
officer at eRT. "eRT's ability to expand capacity and throughput on
a worldwide basis to perform the services associated with these
demanding initiatives has proven critical in enhancing our value
proposition to the global drug development community." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues dueto variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, +1-908-203-6473, or Matt Hayden of Hayden
Communications, +1-760-487-1137 Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles